Health economics and Radium-223 (Xofigo(R)) in the treatment of metastatic castration resistant prostate cancer mCRPC). A case history and a systematic review of the literature on cost effectiveness analysis (CEA). Norum, J., Traasdahl, E. R., Totth, A., Nieder, C., & Olsen, J. A. Value in Health, 7:1, 2015.
Health economics and Radium-223 (Xofigo(R)) in the treatment of metastatic castration resistant prostate cancer mCRPC). A case history and a systematic review of the literature on cost effectiveness analysis (CEA) [link]Paper  doi  bibtex   
@article{norum_health_2015,
	Author = {Norum, Jan and Traasdahl, Erik R. and Totth, Arpad and Nieder, Carsten and Olsen, Jan Abel},
	Doi = {10.1016/j.jval.2015.09.1191},
	Journal = {Value in Health},
	Pages = {1},
	Title = {Health economics and {Radium}-223 ({Xofigo}({R})) in the treatment of metastatic castration resistant prostate cancer {mCRPC}). {A} case history and a systematic review of the literature on cost effectiveness analysis ({CEA})},
	Url = {http://hdl.handle.net/10037/9116},
	Volume = {7},
	Year = {2015},
	Bdsk-Url-1 = {http://hdl.handle.net/10037/9116},
	Bdsk-Url-2 = {https://doi.org/10.1016/j.jval.2015.09.1191}}
%%---------Traasdahl, Erik R end---------------------------------------
%%-------Hjelstuen, Ole Kristian start----------

Downloads: 0